Immunoterapia alergenowa w prewencji i leczeniu astmy Opracowanie: Batard T, Taille C, Guilleminault L et al. Allergen Immunotherapy for the Prevention and Treatment of Asthma
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
maj 12, 2025
Słowa kluczowe:
astma alergiczna, immunoterapia alergenowa, leczenie modyfikujące przebieg choroby, leki biologiczne, profilaktyka, terapia skojarzona
##plugins.themes.bootstrap3.article.main##
Abstrakt
Immunoterapia alergenowa jest jedyną metodą leczenia przyczynowego alergii IgE-zależnej, wykazującą długotrwałe efekty po zakończeniu oraz modyfikującą naturalny przebieg choroby. W kontekście astmy alergicznej odgrywa ona kluczową rolę zarówno w prewencji rozwoju choroby u pacjentów z alergicznym nieżytem nosa, jak i w ograniczaniu jej progresji. Liczne badania potwierdziły, że immunoterapia alergenowa zmniejsza ryzyko rozwoju astmy u pacjentów z alergicznym nieżytem nosa oraz redukuje progresję choroby u osób już chorych. Dodatkowo może ona wspierać leczenie konwencjonalne i biologiczne, poprawiając kontrolę objawów astmy oraz zmniejszając zapotrzebowanie na leki kontrolujące chorobę.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Błażowski, Łukasz. (2025). Immunoterapia alergenowa w prewencji i leczeniu astmy. Alergoprofil, 20(4), 19-26. https://doi.org/10.24292/01.AP.204400525
Numer
Dział
THERAPY
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024.
2. Anderson GP. Endotyping Asthma: New Insights Into Key Pathogenic Mechanisms in a Complex, Heterogeneous Disease. Lancet. 2008; 372(9643): 1107-19.
3. Hambly N, Nair P. Monoclonal Antibodies for the Treatment of Refractory Asthma. Curr Opin Pulm Med. 2014; 20(1): 87-94.
4. Woodruff PG, Modrek B, Choy DF et al. T-Helper Type 2-Driven Inflammation Defines Major Subphenotypes of Asthma. Am J Respir Crit Care Med. 2009; 180(5): 388-95.
5. Peters MC, Mekonnen ZK, Yuan S et al. Measures of Gene Expression in Sputum Cells Can Identify TH2-High and TH- 2-Low Subtypes of Asthma. J Allergy Clin Immunol 2014; 133(2): 388-94.
6. Romanet-Manent S, Charpin D, Magnan A et al. Allergic vs Nonallergic Asthma: What Makes the Difference? Allergy. 2002; 57(7): 607-13.
7. Knudsen TB, Thomsen SF, Nolte H et al. A Population-Based Clinical Study of Allergic and Non-allergic Asthma. J Asthma. 2009; 46(1): 91-4.
8. Lommatzsch M, Brusselle GG, Levy ML et al. A(2)BCD: A Concise Guide for Asthma Management. Lancet Resp Med. 2023; 11(6): 573-6.
9. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. Eur Resp J. 2014; 43(2): 343-73.
10. Lommatzsch M, Buhl R, Canonica GW et al. Pioneering a Paradigm Shift in Asthma Management: Remission as a Treatment Goal. Lancet Resp Med. 2024; 12(2): 96-9.
11. Hekking PW, Wener RR, Amelink M et al. The Prevalence of Severe Refractory Asthma. J Allergy Clin Immunol. 2015; 135(4): 896-902.
12. Akenroye A, McCormack M, Keet C. Severe Asthma in the US Population and Eligibility for mAb Therapy, J Allergy Clin Immunol 2020; 145(4): 1295-7.e1296.
13. Pelaia C, Pelaia G, Crimi C et al. Novel Biological Therapies for Severe Asthma Endotypes. Biomedicines. 2022; 10(5): 1064.
14. Porsbjerg CM, Menzies-Gow AN, Tran TN et al. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. J Allergy Clin Immunol: In Practice. 2022; 10(5): 1202-16.e1223.
15. Guilleminault L, Camus C, Raherison-Semjen C et al. Improvement in Severe Asthma Patients Receiving Biologics and Factors Associated With Persistent Insufficient Control: A Real-Life National Study. Ther Adv Respir Dis. 2023; 17: 17534666231202749.
16. Jackson DJ, Heaney LG, Humbert M et al. Reduction of Daily Maintenance Inhaled Corticosteroids in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (SHAMAL): A Randomised, Multicentre, Open-Label, Phase 4 Study. Lancet. 2024; 403(10423): 271-81.
17. Lommatzsch M, Brusselle GG, Canonica GW et al. Disease-Modifying Anti-Asthmatic Drugs. Lancet. 2022; 399(10335): 1664-8.
18. Pfaar O, Bousquet J, Durham SR et al. One Hundred and Ten Years of Allergen Immunotherapy: A Journey From Empiric Observation to Evidence. Allergy. 2022; 77(2): 454-68.
19. Durham SR, Shamji MH. Allergen Immunotherapy: Past, Present and Future, Nature Reviews. Immunology. 2023; 23(5): 317-28.
20. Larenas-Linnemann D, Morfin Maciel BM. How Can We Improve Our Use of Allergen Immunotherapy as a Treatment Option for Asthma and Severe Asthma? Expert Rev Respir Med. 2023; 17(8): 717-25.
21. Bumbacea RS, Boustani R, Panaitescu C et al. Mechanisms of Allergen Immunotherapy Supporting Its Disease-Modifying Effect. Immunotherapy. 2022; 14(8): 627-38.
22. Layhadi JA, Lalioti A, Palmer E et al. Mechanisms and Predictive Biomarkers of Allergen Immunotherapy in the Clinic. J Allergy Clin Immunol: In Practice. 2024; 12(1): 59-66.
23. Vignola AM, Bousquet J. Rhinitis and Asthma: A Continuum of Disease? Clin Exp Allergy. 2001; 31(5): 674-7.
24. Tsilochristou OA, Douladiris N, Makris M et al. Pediatric Allergic Rhinitis and Asthma: Can the March Be Halted? Paediatr Drugs. 2013; 15(6): 431-40.
25. Linneberg A, Henrik Nielsen N, Frolund L et al. The Link Between Allergic Rhinitis and Allergic Asthma: A Prospective Population-Based Study. The Copenhagen Allergy Study. Allergy. 2002; 57(11): 1048-52.
26. Hannikainen P, Kahn C, Toskala E. Allergic Rhinitis, Rhinosinusitis, and Asthma: Connections Across the Unified Airway. Otolaryngol Clin North Am. 2024; 57(2): 171-8.
27. Lindqvist M, Leth-Moller KB, Linneberg A et al. Natural Course of Pollen-Induced Allergic Rhinitis From Childhood to Adulthood: A 20-Year Follow Up. Allergy. 2024; 79(4): 884-93.
28. Braman SS, Barrows AA, DeCotiis BA et al. Airway Hyperresponsiveness in Allergic Rhinitis. A Risk Factor for Asthma. Chest. 1987; 91(5): 671-4.
29. Anto JM, Sunyer J, Basagana X et al. Risk Factors of New-Onset Asthma in Adults: A Population-Based International Cohort Study. Allergy. 2010; 65(8): 1021-30.
30. Burgess JA, Walters EH, Byrnes GB et al. Childhood Allergic Rhinitis Predicts Asthma Incidence and Persistence to Middle Age: A Longitudinal Study. J Allergy Clin Immunol. 2007; 120(4): 863-9.
31. Shaaban R, Zureik M, Soussan D et al. Rhinitis and Onset of Asthma: A Longitudinal Population-Based Study. Lancet. 2008; 372(9643): 1049-57.
32. Braunstahl GJ, Fokkens WJ, Overbeek SE et al. Mucosal and Systemic Inflammatory Changes in Allergic Rhinitis and Asthma: A Comparison Between Upper and Lower Airways. Clin Exp Allergy. 2003; 33(5): 579-87.
33. Akdis M, Akdis CA. Mechanisms of Allergen-Specific Immunotherapy: Multiple Suppressor Factors at Work in Immune Tolerance to Allergens. J Allergy Clin Immunol. 2014; 133(3): 621-31.
34. Arshad SH. Does Allergen Immunotherapy for Allergic Rhinitis Prevent Asthma? Ann Allergy Asthma Immunol. 2022; 129(3): 286-91.
35. Simons FE. Allergic Rhinobronchitis: The Asthma-Allergic Rhinitis Link. J Allergy Clin Immunol. 1999; 104(3 Pt 1): 534-40.
36. Moller C, Dreborg S, Lanner A et al. Oral Immunotherapy of Children With Rhinoconjunctivitis due to Birch Pollen Allergy. A Double Blind Study. Allergy. 1986; 41(4): 271-9.
37. Jacobsen L, Nuchel Petersen B, Wihl JA et al. Immunotherapy With Partially Purified and Standardized Tree Pollen Extracts. IV. Results From Long-Term (6-Year) Follow-Up. Allergy. 1997; 52(9): 914-20.
38. Grembiale RD, Camporota L, Naty S et al. Effects of Specific Immunotherapy in Allergic Rhinitic Individuals With Bronchial Hyperresponsiveness. Am J Respir Crit Care Med. 2000; 162(6): 2048-52.
39. Jacobsen L, Niggemann B, Dreborg S et al. Specific Immunotherapy Has Long-Term Preventive Effect of Seasonal and Perennial Asthma: 10-Year Follow-Upn on the PAT Study. Allergy. 2007; 62(8): 943-8.
40. Polosa R, Li Gotti F, Mangano G et al. Effect of Immunotherapy on Asthma Progression, BHR and Sputum Eosinophils in Allergic Rhinitis. Allergy. 2004; 59(11): 1224-8.
41. Novembre E, Galli E, Landi F et al. Coseasonal Sublingual Immunotherapy Reduces the Development of Asthma in Children With Allergic Rhinoconjunctivitis. J Allergy Clin Immunol. 2004; 114(4): 851-7.
42. Marogna M, Tomassetti D, Bernasconi A et al. Preventive Effects of Sublingual Immunotherapy in Childhood: An Open Randomized Controlled Study. Ann Allergy Asthma Immunol. 2008; 101(2): 206-11.
43. Peng H, Li CW, Lin ZB et al. Long-Term Efficacy of Specific Immunotherapy on House Dust Mite-Induced Allergic Rhinitis in China. Otolaryngol Head Neck Surg. 2013; 149(1): 40-6.
44. Song W, Lin X, Chai R. Evaluation of Long-Term Effect for House Dust Mite Subcutaneous Immunotherapy for Patients With Allergic Rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015; 50(8): 632-5.
45. Valovirta E, Petersen TH, Piotrowska T et al. Results From the 5-Year SQ Grass Sublingual Immunotherapy Tablet Asthma Prevention (GAP) Trial in Children With Grass Pollen Allergy. J Allergy Clin Immunol. 2018; 141(2): 529-38.e513.
46. Acquistapace F, Agostinis F, Castella V et al. Efficacy of Sublingual Specific Immunotherapy in Intermittent and Persistent Allergic Rhinitis in Children: An Observational Case-Control Study on 171 Patients. The EFESO-Children Multicenter Trial. Pediatr Allergy Immunol. 2009; 20(7): 660-4.
47. Yang J, Lei S. Efficacy and Safety of Sublingual Versus Subcutaneous Immunotherapy in Children With Allergic Rhinitis: A Systematic Review and Meta-Analysis. Front Immunol. 2023; 14: 1274241.
48. Saturni S, Bellini F, Braido F et al. Randomized Controlled Trials and Real Life Studies. Approaches and Methodologies: A Clinical Point of View. Pulm Pharmacol Ther. 2014; 27(2): 129-38.
49. Frieden TR. Evidence for Health Decision Making – Beyond Randomized, Controlled Trials. N Engl J Med. 2017; 377(5): 465-75.
50. Schmitt J, Schwarz K, Stadler E et al. Allergy Immunotherapy for Allergic Rhinitis Effectively Prevents Asthma: Results From a Large Retrospective Cohort Study. J Allergy Clin Immunol. 2015; 136(6): 1511-6.
51. Devillier P, Wahn U, Zielen S et al. Grass Pollen Sublingual Immunotherapy Tablets Provide Long-Term Relief of Grass Pollen-Associated Allergic Rhinitis and Reduce the Risk of Asthma: Findings From a Retrospective, Real-World Database Subanalysis. Expert Rev Clin Immunol. 2017; 13(12): 1199-206.
52. Devillier P, Molimard M, Ansolabehere X et al. Immunotherapy With Grass Pollen Tablets Reduces Medication Dispensing for Allergic Rhinitis and Asthma: A Retrospective Database Study in France. Allergy. 2019; 74(7): 1317-26.
53. Wahn U, Bachert C, Heinrich J et al. Real-World Benefits of Allergen Immunotherapy for Birch Pollen-Associated Allergic Rhinitis and Asthma. Allergy. 2019; 74(3): 594-604.
54. Jutel M, Bruggenjurgen B, Richter H et al. Real-World Evidence of Subcutaneous Allergoid Immunotherapy in House Dust Mite-Induced Allergic Rhinitis and Asthma. Allergy. 2020; 75(8): 2050-8.
55. Zieglmayer P, Devillier P, Richter H et al. Age-Specific Effects of Grass Pollen Allergen Immunotherapy in Reducing theRisk for New Onset Asthma: A Real-World Database Analysis. Allergy. 2023; 78(S111): 20.
56. Devillier P, Molimard M, Bergmann JF et al. A Successful Linkage of a Named Patient Products of Sublingual Immunotherapy- Dispensing Registry to French Healthcare Insurance Database (SNDS): Methodological Constitution of the EfficAPSI Cohort. Expert Rev Clin Immunol. 2023; 20(4): 405-12.
57. Demoly P, Molimard M, Bergmann JF et al. Impact of Liquid Sublingual Immunotherapy on Asthma Onset and Progression in Patients With Allergic Rhinitis: A Nationwide Population- Based Study (EfficAPSI Study). Lancet Regional Health Europe. 2024; 41: 100915.
58. Jutel M, Klimek L, Richter H et al. House Dust Mite SCIT Reduces Asthma Risk and Significantly Improves Long-Term Rhinitis and Asthma Control-A RWE Study. Allergy. 2024; 79(4): 1042-51.
59. Vogelberg C, Klimek L, Kruppert S et al. Long-Term Effects of Pollen Allergoid Tyrosine-Adsorbed Subcutaneous Immunotherapy on Allergic Rhinitis and Asthma. Clin Exp Allergy. 2024; 54(4): 253-64.
60. Gerstlauer M, Zieglmayer P, Richter H et al. Grass Pollen Allergen Immunotherapy Provides Long-Term Relief of Allergic Rhinitis and Asthma in Patients of all Age Classes: A Real World Dataset Analysis. Allergy. 2023; 78(S111): 20-1.
61. Schmitt J, Wustenberg E, Kuster D et al. The Moderating Role of Allergy Immunotherapy in Asthma Progression: Results of a Population-Based Cohort Study. Allergy. 2020; 75(3): 596-602.
62. Ameal A, Vega-Chicote JM, Fernandez S et al. Double-Blind and Placebo-Controlled Study to Assess Efficacy and Safety of a Modified Allergen Extract of Dermatophagoides Pteronyssinus in Allergic Asthma. Allergy. 2005; 60(9): 1178-83.
63. Garcia-Robaina JC, Sanchez I, de la Torre F et al. Successful Management of Mite-Allergic Asthma With Modified Extracts of Dermatophagoides Pteronyssinus and Dermatophagoides Farinae in a Double-Blind, Placebo-Controlled Study. J Allergy Clin Immunol. 2006; 118(5): 1026-32.
64. Jutel M, Rudert M, Kreimendahl F et al. Efficacy and Tolerability of a House Dust Mite Allergoid in Allergic Bronchial Asthma: A Randomized Dose-Ranging Trial. Immunotherapy. 2018; 10(13): 1149-61.
65. Mosbech H, Deckelmann R, de Blay F et al. Standardized Quality (SQ) House Dust Mite Sublingual Immunotherapy Tablet (ALK) Reduces Inhaled Corticosteroid Use While Maintaining Asthma Control: A Randomized, Double-Blind, Placebo-Controlled Trial. J Allergy Clin Immunol. 2014; 134(3): 568-75.e567.
66. Virchow JC, Backer V, Kuna P et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA. 2016; 315(16): 1715-25.
67. Tanaka A, Tohda Y, Okamiya K et al. Efficacy and Safety of HDM SLIT Tablet in Japanese Adults With Allergic Asthma. J Allergy Clin Immunol: In Practice. 2020; 8(2): 710-20.e714.
68. Hoof I, Bonnelykke K, Stranzl T et al. Genetic and T2 Biomarkers Linked to the Efficacy of HDM Sublingual Immunotherapy in Asthma. Thorax. 2024; 79(4): 332-9.
69. Fritzsching B, Contoli M, Porsbjerg C et al. Long-Term Real-World Effectiveness of Allergy Immunotherapy in Patients With Allergic Rhinitis and Asthma: Results From the REACT Study, a Retrospective Cohort Study. Lancet Regional Health – Europe. 2022; 13: 100275.
70. Alvaro-Lozano M, Akdis CA, Akdis M et al. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020; 31(Suppl 25): 1-101.
71. Massanari M, Nelson H, Casale T et al. Effect of Pretreatment With Omalizumab on the Tolerability of Specific Immunotherapy in Allergic Asthma. J Allergy Clin Immunol. 2010; 125(2): 383-9.
72. Larenas-Linnemann D, Wahn U, Kopp M. Use of Omalizumab to Improve Desensitization Safety in Allergen Immunotherapy. J Allergy Clin Immunol. 2014; 133(3): 937.e932.
73. Lambert N, Guiddir T, Amat F et al. Pre-Treatment by Omalizumab Allows Allergen Immunotherapy in Children and Young Adults With Severe Allergic Asthma. Pediatr Allergy Immunol. 2014; 25(8): 829-32.
74. Lambert N, Guiddir T, Just J et al. Pretreatment by Omalizumab Allows Allergen-Specific Immunotherapy in Children and Young Adult With Severe Allergic Asthma. Clin Transl Allergy. 2015; 5: P1.
75. Stelmach I, Majak P, Jerzynska J et al. Children With Severe Asthma Can Start Allergen Immunotherapy After Controlling Asthma With Omalizumab: A Case Series From Poland Archives of Medical Science. 2015; 11(4): 901-4.
76. Mbuila C, Ponvert CL, Mangyanda LK et al. The Impact of Allergen-Specific Immunotherapy in a Polysensitized Child With Severe Respiratory Allergy Treated With Omalizumab. Revue Française d’Allergologie. 2016; 56: 603-7.
77. Carrier C, Demoly P, Caimmi D. Omalizumab and Allergen Immunotherapy: A Clinical Report and Review of the Literature. Revue des Maladies Respiratoires. 2019; 36(2): 191-6.
78. Gulsen A, Wallis S, Jappe U. Combination of Immunotherapies for Severe Allergic Asthma. J Asthma. 2021; 58(1): 75-8.
79. Bozek A, Rogala B, Miodonska M et al. Progressive Clinical Effects of the Combination Omalizumab and HDM – Allergen Immunotherapy in Asthma. J Asthma. 2023; 1-9: 532-8.
80. Olivieri B, Gunaydin FE, Corren J et al. The Combination of Allergen Immunotherapy and Biologics for Inhalant Allergies: Exploring the Synergy. Ann Allergy Asthma Immunol. 2025; 134(4): 385-95.
2. Anderson GP. Endotyping Asthma: New Insights Into Key Pathogenic Mechanisms in a Complex, Heterogeneous Disease. Lancet. 2008; 372(9643): 1107-19.
3. Hambly N, Nair P. Monoclonal Antibodies for the Treatment of Refractory Asthma. Curr Opin Pulm Med. 2014; 20(1): 87-94.
4. Woodruff PG, Modrek B, Choy DF et al. T-Helper Type 2-Driven Inflammation Defines Major Subphenotypes of Asthma. Am J Respir Crit Care Med. 2009; 180(5): 388-95.
5. Peters MC, Mekonnen ZK, Yuan S et al. Measures of Gene Expression in Sputum Cells Can Identify TH2-High and TH- 2-Low Subtypes of Asthma. J Allergy Clin Immunol 2014; 133(2): 388-94.
6. Romanet-Manent S, Charpin D, Magnan A et al. Allergic vs Nonallergic Asthma: What Makes the Difference? Allergy. 2002; 57(7): 607-13.
7. Knudsen TB, Thomsen SF, Nolte H et al. A Population-Based Clinical Study of Allergic and Non-allergic Asthma. J Asthma. 2009; 46(1): 91-4.
8. Lommatzsch M, Brusselle GG, Levy ML et al. A(2)BCD: A Concise Guide for Asthma Management. Lancet Resp Med. 2023; 11(6): 573-6.
9. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. Eur Resp J. 2014; 43(2): 343-73.
10. Lommatzsch M, Buhl R, Canonica GW et al. Pioneering a Paradigm Shift in Asthma Management: Remission as a Treatment Goal. Lancet Resp Med. 2024; 12(2): 96-9.
11. Hekking PW, Wener RR, Amelink M et al. The Prevalence of Severe Refractory Asthma. J Allergy Clin Immunol. 2015; 135(4): 896-902.
12. Akenroye A, McCormack M, Keet C. Severe Asthma in the US Population and Eligibility for mAb Therapy, J Allergy Clin Immunol 2020; 145(4): 1295-7.e1296.
13. Pelaia C, Pelaia G, Crimi C et al. Novel Biological Therapies for Severe Asthma Endotypes. Biomedicines. 2022; 10(5): 1064.
14. Porsbjerg CM, Menzies-Gow AN, Tran TN et al. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. J Allergy Clin Immunol: In Practice. 2022; 10(5): 1202-16.e1223.
15. Guilleminault L, Camus C, Raherison-Semjen C et al. Improvement in Severe Asthma Patients Receiving Biologics and Factors Associated With Persistent Insufficient Control: A Real-Life National Study. Ther Adv Respir Dis. 2023; 17: 17534666231202749.
16. Jackson DJ, Heaney LG, Humbert M et al. Reduction of Daily Maintenance Inhaled Corticosteroids in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (SHAMAL): A Randomised, Multicentre, Open-Label, Phase 4 Study. Lancet. 2024; 403(10423): 271-81.
17. Lommatzsch M, Brusselle GG, Canonica GW et al. Disease-Modifying Anti-Asthmatic Drugs. Lancet. 2022; 399(10335): 1664-8.
18. Pfaar O, Bousquet J, Durham SR et al. One Hundred and Ten Years of Allergen Immunotherapy: A Journey From Empiric Observation to Evidence. Allergy. 2022; 77(2): 454-68.
19. Durham SR, Shamji MH. Allergen Immunotherapy: Past, Present and Future, Nature Reviews. Immunology. 2023; 23(5): 317-28.
20. Larenas-Linnemann D, Morfin Maciel BM. How Can We Improve Our Use of Allergen Immunotherapy as a Treatment Option for Asthma and Severe Asthma? Expert Rev Respir Med. 2023; 17(8): 717-25.
21. Bumbacea RS, Boustani R, Panaitescu C et al. Mechanisms of Allergen Immunotherapy Supporting Its Disease-Modifying Effect. Immunotherapy. 2022; 14(8): 627-38.
22. Layhadi JA, Lalioti A, Palmer E et al. Mechanisms and Predictive Biomarkers of Allergen Immunotherapy in the Clinic. J Allergy Clin Immunol: In Practice. 2024; 12(1): 59-66.
23. Vignola AM, Bousquet J. Rhinitis and Asthma: A Continuum of Disease? Clin Exp Allergy. 2001; 31(5): 674-7.
24. Tsilochristou OA, Douladiris N, Makris M et al. Pediatric Allergic Rhinitis and Asthma: Can the March Be Halted? Paediatr Drugs. 2013; 15(6): 431-40.
25. Linneberg A, Henrik Nielsen N, Frolund L et al. The Link Between Allergic Rhinitis and Allergic Asthma: A Prospective Population-Based Study. The Copenhagen Allergy Study. Allergy. 2002; 57(11): 1048-52.
26. Hannikainen P, Kahn C, Toskala E. Allergic Rhinitis, Rhinosinusitis, and Asthma: Connections Across the Unified Airway. Otolaryngol Clin North Am. 2024; 57(2): 171-8.
27. Lindqvist M, Leth-Moller KB, Linneberg A et al. Natural Course of Pollen-Induced Allergic Rhinitis From Childhood to Adulthood: A 20-Year Follow Up. Allergy. 2024; 79(4): 884-93.
28. Braman SS, Barrows AA, DeCotiis BA et al. Airway Hyperresponsiveness in Allergic Rhinitis. A Risk Factor for Asthma. Chest. 1987; 91(5): 671-4.
29. Anto JM, Sunyer J, Basagana X et al. Risk Factors of New-Onset Asthma in Adults: A Population-Based International Cohort Study. Allergy. 2010; 65(8): 1021-30.
30. Burgess JA, Walters EH, Byrnes GB et al. Childhood Allergic Rhinitis Predicts Asthma Incidence and Persistence to Middle Age: A Longitudinal Study. J Allergy Clin Immunol. 2007; 120(4): 863-9.
31. Shaaban R, Zureik M, Soussan D et al. Rhinitis and Onset of Asthma: A Longitudinal Population-Based Study. Lancet. 2008; 372(9643): 1049-57.
32. Braunstahl GJ, Fokkens WJ, Overbeek SE et al. Mucosal and Systemic Inflammatory Changes in Allergic Rhinitis and Asthma: A Comparison Between Upper and Lower Airways. Clin Exp Allergy. 2003; 33(5): 579-87.
33. Akdis M, Akdis CA. Mechanisms of Allergen-Specific Immunotherapy: Multiple Suppressor Factors at Work in Immune Tolerance to Allergens. J Allergy Clin Immunol. 2014; 133(3): 621-31.
34. Arshad SH. Does Allergen Immunotherapy for Allergic Rhinitis Prevent Asthma? Ann Allergy Asthma Immunol. 2022; 129(3): 286-91.
35. Simons FE. Allergic Rhinobronchitis: The Asthma-Allergic Rhinitis Link. J Allergy Clin Immunol. 1999; 104(3 Pt 1): 534-40.
36. Moller C, Dreborg S, Lanner A et al. Oral Immunotherapy of Children With Rhinoconjunctivitis due to Birch Pollen Allergy. A Double Blind Study. Allergy. 1986; 41(4): 271-9.
37. Jacobsen L, Nuchel Petersen B, Wihl JA et al. Immunotherapy With Partially Purified and Standardized Tree Pollen Extracts. IV. Results From Long-Term (6-Year) Follow-Up. Allergy. 1997; 52(9): 914-20.
38. Grembiale RD, Camporota L, Naty S et al. Effects of Specific Immunotherapy in Allergic Rhinitic Individuals With Bronchial Hyperresponsiveness. Am J Respir Crit Care Med. 2000; 162(6): 2048-52.
39. Jacobsen L, Niggemann B, Dreborg S et al. Specific Immunotherapy Has Long-Term Preventive Effect of Seasonal and Perennial Asthma: 10-Year Follow-Upn on the PAT Study. Allergy. 2007; 62(8): 943-8.
40. Polosa R, Li Gotti F, Mangano G et al. Effect of Immunotherapy on Asthma Progression, BHR and Sputum Eosinophils in Allergic Rhinitis. Allergy. 2004; 59(11): 1224-8.
41. Novembre E, Galli E, Landi F et al. Coseasonal Sublingual Immunotherapy Reduces the Development of Asthma in Children With Allergic Rhinoconjunctivitis. J Allergy Clin Immunol. 2004; 114(4): 851-7.
42. Marogna M, Tomassetti D, Bernasconi A et al. Preventive Effects of Sublingual Immunotherapy in Childhood: An Open Randomized Controlled Study. Ann Allergy Asthma Immunol. 2008; 101(2): 206-11.
43. Peng H, Li CW, Lin ZB et al. Long-Term Efficacy of Specific Immunotherapy on House Dust Mite-Induced Allergic Rhinitis in China. Otolaryngol Head Neck Surg. 2013; 149(1): 40-6.
44. Song W, Lin X, Chai R. Evaluation of Long-Term Effect for House Dust Mite Subcutaneous Immunotherapy for Patients With Allergic Rhinitis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015; 50(8): 632-5.
45. Valovirta E, Petersen TH, Piotrowska T et al. Results From the 5-Year SQ Grass Sublingual Immunotherapy Tablet Asthma Prevention (GAP) Trial in Children With Grass Pollen Allergy. J Allergy Clin Immunol. 2018; 141(2): 529-38.e513.
46. Acquistapace F, Agostinis F, Castella V et al. Efficacy of Sublingual Specific Immunotherapy in Intermittent and Persistent Allergic Rhinitis in Children: An Observational Case-Control Study on 171 Patients. The EFESO-Children Multicenter Trial. Pediatr Allergy Immunol. 2009; 20(7): 660-4.
47. Yang J, Lei S. Efficacy and Safety of Sublingual Versus Subcutaneous Immunotherapy in Children With Allergic Rhinitis: A Systematic Review and Meta-Analysis. Front Immunol. 2023; 14: 1274241.
48. Saturni S, Bellini F, Braido F et al. Randomized Controlled Trials and Real Life Studies. Approaches and Methodologies: A Clinical Point of View. Pulm Pharmacol Ther. 2014; 27(2): 129-38.
49. Frieden TR. Evidence for Health Decision Making – Beyond Randomized, Controlled Trials. N Engl J Med. 2017; 377(5): 465-75.
50. Schmitt J, Schwarz K, Stadler E et al. Allergy Immunotherapy for Allergic Rhinitis Effectively Prevents Asthma: Results From a Large Retrospective Cohort Study. J Allergy Clin Immunol. 2015; 136(6): 1511-6.
51. Devillier P, Wahn U, Zielen S et al. Grass Pollen Sublingual Immunotherapy Tablets Provide Long-Term Relief of Grass Pollen-Associated Allergic Rhinitis and Reduce the Risk of Asthma: Findings From a Retrospective, Real-World Database Subanalysis. Expert Rev Clin Immunol. 2017; 13(12): 1199-206.
52. Devillier P, Molimard M, Ansolabehere X et al. Immunotherapy With Grass Pollen Tablets Reduces Medication Dispensing for Allergic Rhinitis and Asthma: A Retrospective Database Study in France. Allergy. 2019; 74(7): 1317-26.
53. Wahn U, Bachert C, Heinrich J et al. Real-World Benefits of Allergen Immunotherapy for Birch Pollen-Associated Allergic Rhinitis and Asthma. Allergy. 2019; 74(3): 594-604.
54. Jutel M, Bruggenjurgen B, Richter H et al. Real-World Evidence of Subcutaneous Allergoid Immunotherapy in House Dust Mite-Induced Allergic Rhinitis and Asthma. Allergy. 2020; 75(8): 2050-8.
55. Zieglmayer P, Devillier P, Richter H et al. Age-Specific Effects of Grass Pollen Allergen Immunotherapy in Reducing theRisk for New Onset Asthma: A Real-World Database Analysis. Allergy. 2023; 78(S111): 20.
56. Devillier P, Molimard M, Bergmann JF et al. A Successful Linkage of a Named Patient Products of Sublingual Immunotherapy- Dispensing Registry to French Healthcare Insurance Database (SNDS): Methodological Constitution of the EfficAPSI Cohort. Expert Rev Clin Immunol. 2023; 20(4): 405-12.
57. Demoly P, Molimard M, Bergmann JF et al. Impact of Liquid Sublingual Immunotherapy on Asthma Onset and Progression in Patients With Allergic Rhinitis: A Nationwide Population- Based Study (EfficAPSI Study). Lancet Regional Health Europe. 2024; 41: 100915.
58. Jutel M, Klimek L, Richter H et al. House Dust Mite SCIT Reduces Asthma Risk and Significantly Improves Long-Term Rhinitis and Asthma Control-A RWE Study. Allergy. 2024; 79(4): 1042-51.
59. Vogelberg C, Klimek L, Kruppert S et al. Long-Term Effects of Pollen Allergoid Tyrosine-Adsorbed Subcutaneous Immunotherapy on Allergic Rhinitis and Asthma. Clin Exp Allergy. 2024; 54(4): 253-64.
60. Gerstlauer M, Zieglmayer P, Richter H et al. Grass Pollen Allergen Immunotherapy Provides Long-Term Relief of Allergic Rhinitis and Asthma in Patients of all Age Classes: A Real World Dataset Analysis. Allergy. 2023; 78(S111): 20-1.
61. Schmitt J, Wustenberg E, Kuster D et al. The Moderating Role of Allergy Immunotherapy in Asthma Progression: Results of a Population-Based Cohort Study. Allergy. 2020; 75(3): 596-602.
62. Ameal A, Vega-Chicote JM, Fernandez S et al. Double-Blind and Placebo-Controlled Study to Assess Efficacy and Safety of a Modified Allergen Extract of Dermatophagoides Pteronyssinus in Allergic Asthma. Allergy. 2005; 60(9): 1178-83.
63. Garcia-Robaina JC, Sanchez I, de la Torre F et al. Successful Management of Mite-Allergic Asthma With Modified Extracts of Dermatophagoides Pteronyssinus and Dermatophagoides Farinae in a Double-Blind, Placebo-Controlled Study. J Allergy Clin Immunol. 2006; 118(5): 1026-32.
64. Jutel M, Rudert M, Kreimendahl F et al. Efficacy and Tolerability of a House Dust Mite Allergoid in Allergic Bronchial Asthma: A Randomized Dose-Ranging Trial. Immunotherapy. 2018; 10(13): 1149-61.
65. Mosbech H, Deckelmann R, de Blay F et al. Standardized Quality (SQ) House Dust Mite Sublingual Immunotherapy Tablet (ALK) Reduces Inhaled Corticosteroid Use While Maintaining Asthma Control: A Randomized, Double-Blind, Placebo-Controlled Trial. J Allergy Clin Immunol. 2014; 134(3): 568-75.e567.
66. Virchow JC, Backer V, Kuna P et al. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial. JAMA. 2016; 315(16): 1715-25.
67. Tanaka A, Tohda Y, Okamiya K et al. Efficacy and Safety of HDM SLIT Tablet in Japanese Adults With Allergic Asthma. J Allergy Clin Immunol: In Practice. 2020; 8(2): 710-20.e714.
68. Hoof I, Bonnelykke K, Stranzl T et al. Genetic and T2 Biomarkers Linked to the Efficacy of HDM Sublingual Immunotherapy in Asthma. Thorax. 2024; 79(4): 332-9.
69. Fritzsching B, Contoli M, Porsbjerg C et al. Long-Term Real-World Effectiveness of Allergy Immunotherapy in Patients With Allergic Rhinitis and Asthma: Results From the REACT Study, a Retrospective Cohort Study. Lancet Regional Health – Europe. 2022; 13: 100275.
70. Alvaro-Lozano M, Akdis CA, Akdis M et al. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020; 31(Suppl 25): 1-101.
71. Massanari M, Nelson H, Casale T et al. Effect of Pretreatment With Omalizumab on the Tolerability of Specific Immunotherapy in Allergic Asthma. J Allergy Clin Immunol. 2010; 125(2): 383-9.
72. Larenas-Linnemann D, Wahn U, Kopp M. Use of Omalizumab to Improve Desensitization Safety in Allergen Immunotherapy. J Allergy Clin Immunol. 2014; 133(3): 937.e932.
73. Lambert N, Guiddir T, Amat F et al. Pre-Treatment by Omalizumab Allows Allergen Immunotherapy in Children and Young Adults With Severe Allergic Asthma. Pediatr Allergy Immunol. 2014; 25(8): 829-32.
74. Lambert N, Guiddir T, Just J et al. Pretreatment by Omalizumab Allows Allergen-Specific Immunotherapy in Children and Young Adult With Severe Allergic Asthma. Clin Transl Allergy. 2015; 5: P1.
75. Stelmach I, Majak P, Jerzynska J et al. Children With Severe Asthma Can Start Allergen Immunotherapy After Controlling Asthma With Omalizumab: A Case Series From Poland Archives of Medical Science. 2015; 11(4): 901-4.
76. Mbuila C, Ponvert CL, Mangyanda LK et al. The Impact of Allergen-Specific Immunotherapy in a Polysensitized Child With Severe Respiratory Allergy Treated With Omalizumab. Revue Française d’Allergologie. 2016; 56: 603-7.
77. Carrier C, Demoly P, Caimmi D. Omalizumab and Allergen Immunotherapy: A Clinical Report and Review of the Literature. Revue des Maladies Respiratoires. 2019; 36(2): 191-6.
78. Gulsen A, Wallis S, Jappe U. Combination of Immunotherapies for Severe Allergic Asthma. J Asthma. 2021; 58(1): 75-8.
79. Bozek A, Rogala B, Miodonska M et al. Progressive Clinical Effects of the Combination Omalizumab and HDM – Allergen Immunotherapy in Asthma. J Asthma. 2023; 1-9: 532-8.
80. Olivieri B, Gunaydin FE, Corren J et al. The Combination of Allergen Immunotherapy and Biologics for Inhalant Allergies: Exploring the Synergy. Ann Allergy Asthma Immunol. 2025; 134(4): 385-95.